RhumbLine Advisers
ELEV

RhumbLine Advisers’s Elevation Oncology ELEV Stock Holding History

RhumbLine Advisers’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-78,732
Closed -$20.4K – 4179
2025
Q1 		$20.4K Buy
78,732
+8,697
+12% +$4.96K ﹤0.01% 3734
2024
Q4 		$39.4K Buy
70,035
+5,429
+8% +$3.21K ﹤0.01% 3705
2024
Q3 		$38.8K Sell
64,606
-304
-0.5% -$451 ﹤0.01% 3726
2024
Q2 		$175K Buy
+64,910
New +$244K ﹤0.01% 3303

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

RhumbLine Advisers's ELEV Position: Q2 2025 in Review

RhumbLine Advisers sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 78,732 shares — an estimated $20.4K sold.

RhumbLine Advisers first reported a position in ELEV in Q2 2024 and held it in 4 quarters. The position peaked at $175K in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • RhumbLine Advisers reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 78,732 Elevation Oncology shares in Q2 2025, an estimated $20.4K.
  • RhumbLine Advisers first reported a position in Elevation Oncology in Q2 2024 and held it in 4 quarters.
  • RhumbLine Advisers's Elevation Oncology position peaked at $175K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.